# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price...
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...
Canaccord Genuity analyst Caitlin Cronin reiterates Axogen (NASDAQ:AXGN) with a Buy and maintains $15 price target.
The company anticipates the BLA filing to be completed in the third quarter of 2024 and believe the procedural timelines for re...
Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14....
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...